Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23783636 | 0.84 | CHRNA7 (0.41) | LOXL2PRMT5WDR77CYP11B1CYP11B2 | |
| SCHEMBL2560682 | 0.83 | ADORA2A (0.43) | PRMT5WDR77CYP11B1CYP11B2HTT | |
| SCHEMBL1413439 | 0.79 | CYP11B1 (0.47) | CYP11B1CYP11B2ADORA2AADORA1HRH3 | |
| SCHEMBL29625378 | 0.79 | CYP11B1 (0.38) | CYP11B1CYP11B2HTTADORA2AADORA1 | |
| SCHEMBL30044994 | 0.79 | CYP11B1 (0.47) | CYP11B1CYP11B2ADORA2AADORA1HRH3 | |
| SCHEMBL1161457 | 0.79 | CYP11B1 (0.38) | CYP11B1CYP11B2HTTADORA2AADORA1 | |
| SCHEMBL19911768 | 0.79 | CYP11B2 (0.47) | CYP11B1CYP11B2HTTADORA2AADORA1 | |
| SCHEMBL31446925 | 0.79 | CYP11B2 (0.47) | CYP11B1CYP11B2HTTADORA2AADORA1 | |
| SCHEMBL1413419 | 0.79 | GRIN2B (0.40) | CYP11B1CYP11B2HRH3RAF1GRIN1 | |
| SCHEMBL7673123 | 0.79 | CYP11B1 (0.38) | PRMT5WDR77CYP11B1CYP11B2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683919-A1 | VANIN-1 INHIBITORS | Athos Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024196841-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2020249785-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020244518-A1 | COMPOUND WITH BENZYLOXY AROMATIC RING STRUCTURE, PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2020-12-10 | — | — | WO | disclosed |
| WO-2020244518-A1 | COMPOUND WITH BENZYLOXY AROMATIC RING STRUCTURE, PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2020-12-10 | — | — | WO | disclosed |
| EP-3675856-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-0161737-B1 | ELECTROCHEMICAL REDUCTIONS OF CYANOPYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| US-5002949-A | Anticoagulants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0161737-A1 | Electrochemical reductions of cyanopyridine bases | REILLY INDUSTRIES, INC. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4482437-A | Electrochemical reductions of cyanopyridine bases | REILLY TAR & CHEMICAL CORP. (US) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066353-A1 | VANIN-1 INHIBITORS | VCAM1, TMBIM6, VNN1 | LOXL2 714/4885PRMT5 3227/4885WDR77 3295/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | LOXL2 2380/4885PRMT5 3091/4885WDR77 3847/4885 |
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | LOXL2 3480/4885PRMT5 1920/4885WDR77 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.